Figure 1.
![Study design. ∗In the lenalidomide arm, venous thromboembolism prophylaxis with either low-molecular weight heparins or aspirin is mandatory (according to institutional guidelines). †Rituximab (375 mg/m2) and CHOP chemotherapy included cyclophosphamide (750 mg/m2 IV), doxorubicin (50 mg/m2 IV), and vincristine (1.4 mg/m2 [maximum dose = 2 mg] IV) on day 1 of every 21-day cycle and prednisone/prednisolone (100 mg/day PO) on days 1 to 5. The day 1 steroid dose being part of CHOP (100 mg prednisone/prednisolone, or equivalent, PO or IV) could be used as a further component of premedication before tafasitamab infusion. L, lenalidomide; NOS, not otherwise specified; PO, orally; R, randomized; T, tafasitamab.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/142/16/10.1182_blood.2023020637/2/blood_bld-2023-020637-gr1.jpeg?Expires=1719014164&Signature=Vc9NgsZyIj6KwPdtUgjMYJqYX1JqKaLze9KeejfAU9Rvpr9vqBnbGCf-m-Qgz5MAbi2rYH6TDAdTuPrufT53vGDFdHqN3gn-bGs7oWMMf3vig1DXxgmf~0IxlL~6IJEeYHFYjk-luMfzRwE2MpBWOze8nyy7FnNhmL8saVj~dZ98EVa7EGMzFjdaxS55cuUVdmEJxDARf1hQTrpqBQPp-wSq8Fg7V5sEGIi20PK0TrJW7ZpFQBqFd-QrxDbVH3GgtBeDMWeDKuy6WH1iblTrsIcZGoCat4J4VkkoZ6S51EJsNWhHrE~rQFyAXSsJCS5slfdYnBJP7daqrQxKCBiOvQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Study design. ∗In the lenalidomide arm, venous thromboembolism prophylaxis with either low-molecular weight heparins or aspirin is mandatory (according to institutional guidelines). †Rituximab (375 mg/m2) and CHOP chemotherapy included cyclophosphamide (750 mg/m2 IV), doxorubicin (50 mg/m2 IV), and vincristine (1.4 mg/m2 [maximum dose = 2 mg] IV) on day 1 of every 21-day cycle and prednisone/prednisolone (100 mg/day PO) on days 1 to 5. The day 1 steroid dose being part of CHOP (100 mg prednisone/prednisolone, or equivalent, PO or IV) could be used as a further component of premedication before tafasitamab infusion. L, lenalidomide; NOS, not otherwise specified; PO, orally; R, randomized; T, tafasitamab.
